mifepristone | C29H35NO2 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/55245#section=Top
`
`NIH
`
`U.S. National Library of Medicine
`
`National Center for Biotechnology Information
`
`Compound Summary for CID 55245
`
`Cite this Record
`
`STRUCTURE
`
`VENDORS
`
`DRUG INFO
`
`PHARMACOLOGY
`
`LITERATURE
`
`PATENTS
`
`BIOACTIVITIES
`
`PubChem CID:
`
`55245
`
`Chemical Names:
`
`Mifepristone; 84371-65-3; Mifeprex; Mifegyne; RU-486; Mifepriston    More...
`
`Molecular Formula:
`Molecular Weight:
`InChI Key:
`
`C H NO
`29 35
`2
`429.604 g/mol
`VKHAHZOOUSRJNA-GCNJZUOMSA-N
`
`Drug Information:
`
`Drug Indication    Therapeutic Uses    Clinical Trials    FDA Orange Book   
`
`FDA UNII
`
`Safety Summary:
`
`Laboratory Chemical Safety Summary (LCSS)
`
`Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding
`during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or
`decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with
`nonpituitary CUSHING SYNDROME.
`
`from MeSH
`
`Mifepristone is a Progestin Antagonist. The mechanism of action of mifepristone is as a Progestational Hormone
`Receptor Antagonist.
`
`FDA Pharmacology Summary from FDA Pharm Classes
`
`Mifepristone is a derivative of the synthetic progestin norethindrone with antiprogesterone activity. Mifepristone
`competitively binds to the progesterone receptor, resulting in inhibition of the effects of endogenous or exogenous
`progesterone. This agent also exhibits antiglucocorticoid and weak antiandrogenic activities.
`
`1 of 56
`
`1/8/2018, 8:39 AM
`
`

`

`mifepristone | C29H35NO2 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/55245#section=Top
`
`PUBCHEM COMPOUND MIFEPRISTONE
`
`Modify Date: 2018-01-06; Create Date: 2005-06-24
`
`Pharmacology from NCIt
`
`2 of 56
`
`1/8/2018, 8:39 AM
`
`

`

`mifepristone | C29H35NO2 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/55245#section=Top
`
`1 2D Structure
`2 3D Conformer
`3 Names and Identifiers
`4 Chemical and Physical Properties
`5 Related Records
`6 Chemical Vendors
`7 Drug and Medication Information
`8 Pharmacology and Biochemistry
`9 Use and Manufacturing
`10 Safety and Hazards
`11 Toxicity
`12 Literature
`13 Patents
`14 Biomolecular Interactions and Pathways
`15 Biological Test Results
`16 Classification
`17 Information Sources
`
`3 of 56
`
`1/8/2018, 8:39 AM
`
`

`

`mifepristone | C29H35NO2 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/55245#section=Top
`
`Search
`
`Download
`
`Get Image
`
`Magnify
`
`from PubChem
`
`4 of 56
`
`1/8/2018, 8:39 AM
`
`

`

`mifepristone | C29H35NO2 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/55245#section=Top
`
`Search
`
`Download
`
`Get Image
`
`   
`  
` 
` 
` 
`  
`     
`   
`
` 
`
` 
`
`      
`
` 
`  
`   
`  
`
` 
`
` 
`
` 
`
` 
`
` 
`
` 
`
` 
`
` 
`
` 
`
`  
`  
`     
` 
`  
` 
` 
` 
` 
`  
`  
`   
` 
` 
` 
`  
` 
` 
`  
`    
` 
`      
` 
`  
`        
`     
`    
`     
` 
`  
`
` 
` 
` 
`
` 
`
` 
`
` 
`
` 
`
`Magnify
`
`Show Hydrogens
`
`Show Atoms
`
`Animate
`
`from PubChem
`
`5 of 56
`
`1/8/2018, 8:39 AM
`
`

`

`mifepristone | C29H35NO2 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/55245#section=Top
`
`3.1 Computed Descriptors
`
`3.1.1 IUPAC Name
`(8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-
`decahydrocyclopenta[a]phenanthren-3-one
`
`from PubChem
`
`3.1.2 InChI
`InChI=1S/C29H35NO2
`/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4
`/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1
`
`3.1.3 InChI Key
`VKHAHZOOUSRJNA-GCNJZUOMSA-N
`
`3.1.4 Canonical SMILES
`CC#CC1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O
`
`from PubChem
`
`from PubChem
`
`from PubChem
`
`3.1.5 Isomeric SMILES
`CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O
`from PubChem
`
`3.2 Molecular Formula
`C H NO
`29 35
`
`2
`
`3.3 Other Identifiers
`
`from PubChem
`
`6 of 56
`
`1/8/2018, 8:39 AM
`
`

`

`mifepristone | C29H35NO2 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/55245#section=Top
`
`3.3.1 CAS
`84371-65-3
`
`
`from ChemIDplus, DrugBank, EPA DSStox, European Chemicals Agency - ECHA, Human Metabolome Databa…
`
`3.3.2 EC Number
`617-559-7
`
`3.3.3 UNII
`320T6RNW1F
`
`3.3.4 Wikipedia
`
`Title
`Description
`
`3.4 Synonyms
`
`from European Chemicals Agency - ECHA
`
`from DrugBank, FDA/SPL Indexing Data
`
`mifepristone
`chemical compound
`
`from Wikipedia
`
`3.4.1 MeSH Entry Terms
`Mifégyne
`1.
`RU-48611.
`
`Mifegyne
`2.
`
`RU3848612.
`Mifeprex
`3.
`
`RU48613.
`Mifepristone
`4.
`
`ZK 9829614.
`R 38486
`5.
`
`ZK-9829615.
`R-38486
`6.
`
`ZK9829616.
`R38486
`7.
`RU 38486
`8.
`RU 486
`9.
`RU-38486
`10.
`
`7 of 56
`
`1/8/2018, 8:39 AM
`
`from MeSH
`
`

`

`mifepristone | C29H35NO2 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/55245#section=Top
`
`3.4.2 Depositor-Supplied Synonyms
`Mifepristonum [Latin]11.
`
`mifepristone
`1.
`
`RU48612.
`84371-65-3
`2.
`
`Mifepristona [Spanish]13.
`Mifeprex
`3.
`
`RU 48614.
`Mifegyne
`4.
`
`RU-3848615.
`RU-486
`5.
`
`RU 3848616.
`Mifepriston
`6.
`
`UNII-320T6RNW1F17.
`Corlux
`7.
`
`Mifepristone [USAN:INN:BAN]18.
`Mifepristona
`8.
`
`HSDB 684119.
`Mifepristonum
`9.
`
`R 3848620.
`Korlym
`10.
`
`21.
`22.
`23.
`24.
`25.
`26.
`27.
`28.
`29.
`30.
`
`BRN 5779404
`RU 486-6
`MLS000069785
`320T6RNW1F
`VGX-410C
`CHEBI:50692
`VGX-410
`NCGC00025179-05
`SMR000058481
`DSSTox_CID_3322
`
`31.
`32.
`33.
`34.
`35.
`36.
`37.
`38.
`39.
`40.
`
`11beta-(4-(Dimethylamino)ph
`17-beta-Hydroxy-11-beta-(4-
`DSSTox_RID_76976
`DSSTox_GSID_23322
`(8S,11R,13S,14S,17S)-11-(4-d
`(8S,11R,13S,14S,17S)-11-[4-(d
`11beta-(4-(Dimethylamino)ph
`11beta-(4-(N,N-Dimethylami
`11beta-(p-(Dimethylamino)p
`ZK-98296
`
`from PubChem
`
`8 of 56
`
`1/8/2018, 8:39 AM
`
`

`

`mifepristone | C29H35NO2 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/55245#section=Top
`
`4.1 Computed Properties
`
`Property Name
`Molecular Weight
`Hydrogen Bond Donor Count
`Hydrogen Bond Acceptor Count
`Rotatable Bond Count
`Complexity
`
`CACTVS Substructure Key Fingerprint
`
`Topological Polar Surface Area
`Monoisotopic Mass
`Exact Mass
`XLogP3-AA
`Compound Is Canonicalized
`Formal Charge
`Heavy Atom Count
`Defined Atom Stereocenter Count
`Undefined Atom Stereocenter Count
`Defined Bond Stereocenter Count
`Undefined Bond Stereocenter Count
`Isotope Atom Count
`Covalently-Bonded Unit Count
`
`4.2 Experimental Properties
`
`4.2.1 Physical Description
`Solid
`
`Property Value
`429.604 g/mol
`1
`3
`3
`921
`AAADcfB6MAAAAAAAAAAAAAAAAAAAAYAAAAAwYIEA
`AAAAAGCBAAAAHgAACAAAD0yBmAQywIMAAgDIEqRS
`QAiCAAAhAgAIiAEIZMgIIDLAkZGEYAhkgABIyQeYyPCPiA
`AAAAAAAACQAAQAACAAAYAADAAAAA==
`40.5 A^2
`429.267 g/mol
`429.267 g/mol
`3.8
`true
`0
`32
`5
`0
`0
`0
`0
`1
`
`from PubChem
`
`from Human Metabolome Database (HMDB)
`
`9 of 56
`
`1/8/2018, 8:39 AM
`
`

`

`mifepristone | C29H35NO2 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/55245#section=Top
`
`4.2.2 Color
`Yellow powder
`FDA; Mifeprex (mifeprestone) Information. Mifeprex label. Washington DC: Food Drug Admin, Cntr Drug Eval Res. Available from, as
`of Jan 28, 2005: http://www.fda.gov/cder/foi/label/2004/020687lbl_Revised.pdf
`
`4.2.3 Melting Point
`191-196 °C
`FDA Label
`
`from HSDB
`
`from DrugBank
`
`150 deg C
`O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. 13th Edition, Whitehouse Station, NJ:
`Merck and Co., Inc., 2001., p. 1103
`
`191 - 196 °C
`
`4.2.4 Solubility
`7 [ug/mL]
`
`Water Solubility
`Poorly soluble
`FDA Label
`
`from HSDB
`
`from Human Metabolome Database (HMDB)
`
`from Burnham Center for Chemical Genomics
`
`from DrugBank
`
`Very soluble in methanol, chloroform, and acetone and poorly soluble in water, hexane, and isopropyl ether.
`FDA; Mifeprex (mifeprestone) Information. Mifeprex label. Washington DC: Food Drug Admin, Cntr Drug Eval Res. Available from, as
`of Jan 28, 2005: http://www.fda.gov/cder/foi/label/2004/020687lbl_Revised.pdf
`
`from HSDB
`
`In water, 5.0X10-2 mg/L at 25 deg C /Estimated/
`US EPA; Estimation Programs Interface (EPI). ver. 3.11. U.S. EPA version for Windows. Washington, DC: U.S. EPA (2003). Available
`from, as of Dec. 15, 2004: http://www.epa.gov/oppt/exposure/pubs/episuitedl.htm
`
`3.36e-03 g/L
`
`from HSDB
`
`from Human Metabolome Database (HMDB)
`
`10 of 56
`
`1/8/2018, 8:39 AM
`
`

`

`mifepristone | C29H35NO2 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/55245#section=Top
`
`4.2.5 Vapor Pressure
`8.0X10-14 mm Hg at 25 deg C /Estimated/
`US EPA; Estimation Programs Interface (EPI). ver. 3.11. U.S. EPA version for Windows. Washington, DC: U.S. EPA (2003). Available
`from, as of Dec. 15, 2004: http://www.epa.gov/oppt/exposure/pubs/episuitedl.htm
`
`from HSDB
`
`4.2.6 LogP
`4.5
`
`from DrugBank, Human Metabolome Database (HMDB)
`
`log Kow = 5.4 /Estimated/
`US EPA; Estimation Programs Interface (EPI). ver. 3.11. U.S. EPA version for Windows. Washington, DC: U.S. EPA (2003). Available
`from, as of Dec. 15, 2004: http://www.epa.gov/oppt/exposure/pubs/episuitedl.htm
`
`from HSDB
`
`4.3 Spectral Properties
`Specific optical rotation: +138.5 deg at 20 deg C/D (concentration by volume = 0.5 g in 100 ml chloroform)
`O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. 13th Edition, Whitehouse Station, NJ:
`Merck and Co., Inc., 2001., p. 1103
`
`from HSDB
`
`4.3.1 Infrared Spectra
`
`Infrared Spectra: 1 of 2 (FTIR Spectra)
`Instrument Name
`Bio-Rad FTS
`Technique
`KBr1 0.73mg
`Source of Spectrum
`Forensic Spectral Research
`Source of Sample
`Steraloids
`Catalog Number
`E0170-000
`Lot Number
`H416
`Copyright
`Copyright © 2008-2017 Bio-Rad Laboratories, Inc. All Rights Reserved.
`
`11 of 56
`
`1/8/2018, 8:39 AM
`
`

`

`mifepristone | C29H35NO2 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/55245#section=Top
`
`Infrared Spectra: 1 of 2 (FTIR Spectra)
`
`Thumbnail
`
`from SpectraBase
`
`Infrared Spectra: 2 of 2 (ATR-IR Spectra)
`Instrument Name
`Bio-Rad FTS
`Technique
`ATR-Neat (DuraSamplIR II) ground
`Source of Spectrum
`Forensic Spectral Research
`Source of Sample
`Steraloids Inc.
`Catalog Number
`E0170-000
`Lot Number
`H416
`Copyright
`Copyright © 2009-2017 Bio-Rad Laboratories, Inc. All Rights Reserved.
`
`Thumbnail
`
`12 of 56
`
`from SpectraBase
`
`1/8/2018, 8:39 AM
`
`

`

`mifepristone | C29H35NO2 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/55245#section=Top
`
`4.3.2 Raman Spectra
`
`13 of 56
`
`1/8/2018, 8:39 AM
`
`

`

`mifepristone | C29H35NO2 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/55245#section=Top
`
`Technique
`FT-Raman
`
`Source of Spectrum
`Forensic Spectral Research
`
`Source of Sample
`Steraloids Inc.
`
`Catalog Number
`E0170-000
`
`Lot Number
`H416
`
`Copyright
`Copyright © 2013-2017 Bio-Rad Laboratories, Inc. All Rights Reserved.
`
`Thumbnail
`
`from SpectraBase
`
`from SpectraBase
`
`from SpectraBase
`
`from SpectraBase
`
`from SpectraBase
`
`from SpectraBase
`
`from SpectraBase
`
`14 of 56
`
`1/8/2018, 8:39 AM
`
`

`

`mifepristone | C29H35NO2 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/55245#section=Top
`
`4.3.3 1D NMR Spectra
`
`1H NMR Spectra
`13C NMR Spectra
`
`1D NMR Spectrum 2674 - JEOL 400 MHz 1H NMR
`1D NMR Spectrum 3360 - 50.18 MHz 13C NMR
`
`from Human Metabolome Database (HMDB)
`
`from Human Metabolome Database (HMDB)
`
`from Human Metabolome Database (HMDB)
`
`4.3.4 Mass Spectrometry
`
`4.3.4.1 GC-MS
`
`1.
`2.
`
`GC-MS Spectrum 18007
`GC-MS Spectrum 40508
`
`4.3.4.2 MS-MS
`
`1.
`2.
`3.
`4.
`5.
`6.
`7.
`8.
`
`MS-MS Spectrum 105366
`MS-MS Spectrum 105367
`MS-MS Spectrum 105368
`MS-MS Spectrum 171843
`MS-MS Spectrum 171844
`MS-MS Spectrum 171845
`MS-MS Spectrum 451186
`MS-MS Spectrum 451621
`
`NIST Number
`Instrument Type
`Collision Energy
`Spectrum Type
`Precursor Type
`Precursor m/z
`Total Peaks
`m/z Top Peak
`m/z 2nd Highest
`m/z 3rd Highest
`
`1212359
`IT/ion trap
`0
`MS2
`[M+H]+
`430.2741
`240
`372.3
`412.3
`415.3
`
`15 of 56
`
`1/8/2018, 8:39 AM
`
`

`

`mifepristone | C29H35NO2 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/55245#section=Top
`
`Thumbnail
`
`from NIST
`
`16 of 56
`
`1/8/2018, 8:39 AM
`
`

`

`mifepristone | C29H35NO2 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/55245#section=Top
`
`Download
`
`Chemical Information
`Molecular Biology Databases
`Molecular Biology Databases
`Molecular Biology Databases
`Molecular Biology Databases
`Chemical Information
`
`Ingenuity Pathways Analysis
`Receptor: Glucocorticoid receptor - Nuclear Receptor Signaling Atlas (NURSA)
`Receptor: Progesterone receptor - Nuclear Receptor Signaling Atlas (NURSA)
`Receptor: Mineralocorticoid receptor - Nuclear Receptor Signaling Atlas (NURSA)
`Receptor: Androgen receptor - Nuclear Receptor Signaling Atlas (NURSA)
`Side effects of mifepristone - SIDER Side Effect Resource
`
`from NCBI
`
`Download
`
`from PubChem
`
`5.1 Related Compounds with Annotation
`
`Medications (1)
`
`Literature (31)
`
`3D Structure (2)
`
`Bioactivities (119)
`
`Patents (623)
`
`ulipristal acetate
`
`5.2 Related Compounds
`
`Same Tautomer
`Same Connectivity
`Same Stereo
`Same Isotope
`Same Parent, Tautomer
`Same Parent, Connectivity
`Same Parent, Stereo
`Same Parent, Isotope
`
`72 records
`70 records
`39 records
`32 records
`73 records
`71 records
`40 records
`33 records
`
`17 of 56
`
`1/8/2018, 8:39 AM
`
`

`

`mifepristone | C29H35NO2 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/55245#section=Top
`
`Same Parent, Exact
`Mixtures, Components, and
`Neutralized Forms
`Similar Compounds
`Similar Conformers
`
`2 records
`
`65 records
`
`1002 records
`518 records
`
`5.3 Substances
`
`5.3.1 Related Substances
`
`All
`Same
`Mixture
`
`266 records
`180 records
`86 records
`
`5.3.2 Substances by Category
`
`Chemical Vendors (60)
`Curation Efforts (20)
`Governmental Organizations (45)
`Journal Publishers (5)
`NIH Initiatives (18)
`Research and Development (59)
`Subscription Services (7)
`Legacy Depositors (7)
`
`5.4 Entrez Crosslinks
`
`PubMed
`Protein Structures
`
`299 records
`3 records
`
`from PubChem
`
`from PubChem
`
`Download
`
`from PubChem
`
`18 of 56
`
`1/8/2018, 8:39 AM
`
`

`

`mifepristone | C29H35NO2 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/55245#section=Top
`
`Taxonomy
`OMIM
`Gene
`
`17 records
`5 records
`683 records
`
`from PubChem
`
`19 of 56
`
`1/8/2018, 8:39 AM
`
`

`

`mifepristone | C29H35NO2 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/55245#section=Top
`
`Vendor/Supplier
`
`Finetech Industry Limited
`
`1717 CheMall Corporation
`Hangzhou Trylead Chemical Technology
`Aronis
`OChem
`A&J Pharmtech CO., LTD.
`
`Sigma-Aldrich
`
`CambridgeChem
`MedChemexpress MCE
`ApexBio Technology
`Race Chemical
`Axon Medchem
`TargetMol
`eNovation Chemicals
`Tocris Bioscience
`Ark Pharm, Inc.
`EMD Millipore
`ChemScene
`
`AvaChem Scientific
`
`AKos Consulting & Solutions
`AbovChem LLC
`
`Aurora Fine Chemicals LLC
`
`Tractus
`Parchem
`
`Refine/Analyze
`Purchasable Chemical
`FT-0082666
`FT-0602519
`PL008707
`TL8005515
`ARONIS27015
`4278
`AJ-45776
`1443759_USP
`M8046_SIGMA
`DB27524
`HY-13683
`B1511
`RV022504426
`1502
`T1102-2mg
`D488421
`1479
`AK128404
`475838
`CS-1435
`3051
`84371-65-3
`AKOS015895416
`HY-13683
`A17.877.283
`K06.334.130
`TR-026092
`29428
`
`Download
`PubChem SID
`118048663
`164787698
`254561904
`49835339
`160873956
`341834439
`223554947
`329750468
`24278572
`318357765
`210280566
`318153832
`252215796
`252160201
`312701012
`319462895
`241182464
`176250055
`163687678
`163686090
`251917841
`251916494
`152034835
`319554000
`310105000
`289671535
`204366785
`316967263
`
`20 of 56
`
`1/8/2018, 8:39 AM
`
`

`

`mifepristone | C29H35NO2 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/55245#section=Top
`
`Chembase.cn
`AN PharmaTech
`ChemShuttle
`ACT Chemical
`
`LGC Standards
`
`Acorn PharmaTech Product List
`LabNetwork, a WuXi AppTec Company
`Biosynth
`Amadis Chemical
`ZINC
`Glentham Life Sciences Ltd.
`AHH Chemical co.,ltd
`Selleckchem
`Pi Chemicals
`Ambinter
`AOBIOUS INC
`iChemical
`Boc Sciences
`Chem-Space.com Database
`Active Biopharma
`Chemieliva Pharmaceutical Co., Ltd
`Phion Ltd
`labseeker
`ChemTik
`Anward
`Aurum Pharmatech LLC
`ABBLIS Chemicals
`Wubei-Biochem
`Clearsynth
`Changzhou Highassay Chemical Co., Ltd
`
`713
`AN-10301
`151746
`ACT02598
`LGCAMP1007.00-11
`LGCFOR1007.00
`MM1007.00
`ACN-037299
`LN00196309
`Q-201405
`A840767
`ZINC3831128
`GP8226
`MT-54300
`S2606
`PI-10798
`Ambap84371-65-3
`AOB6893
`EBD34708
`84371-65-3
`CSC020619121
`ABP000437
`PBCM0869006
`17727697
`SC-16222
`CTK8B2959
`ANW-41472
`W-5163
`AB2000695
`WB447825ST
`CS-O-30640
`my_sub2604
`
`160964176
`223682877
`329590209
`165235219
`340514805
`340516056
`340520469
`329847217
`346695359
`255370371
`131327648
`330112193
`310277242
`252352356
`347912794
`322070050
`119526316
`252451527
`318038765
`312811056
`319039987
`152344288
`349350864
`315445570
`318166417
`163087873
`160808972
`184812036
`135692549
`342404818
`313077481
`313081523
`
`21 of 56
`
`from PubChem
`
`1/8/2018, 8:39 AM
`
`

`

`mifepristone | C29H35NO2 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/55245#section=Top
`
`22 of 56
`
`1/8/2018, 8:39 AM
`
`

`

`mifepristone | C29H35NO2 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/55245#section=Top
`
`7.1 Drug Indication
`For the medical termination of intrauterine pregnancy through 49 days' pregnancy. Also indicated to control
`hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2
`diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery.
`from DrugBank
`
`FDA Label
`
`from DrugBank
`
`7.2 LiverTox Summary
`Mifepristone, also known as RU-486, is a potent synthetic steroidal antiprogesterone which is used in combination
`with misoprostol, a prostaglandin analogue, to induce medical abortion. Mifepristone with misoprostol have not been
`associated with serum enzyme elevations or with clinically apparent liver injury.
`
`7.3 Drug Classes
`Pregnancy Termination Agents
`
`7.4 FDA Medication Guides
`Mifeprex (mifepristone) [2016 version]
`
`Korlym (mifepristone) [5/2017 version]
`
`7.5 FDA Orange Book
`
`7.5.1 Prescription Drug Products
`
`from LiverTox
`
`from LiverTox
`
`from FDA Medication Guides
`
`from FDA Medication Guides
`
`23 of 56
`
`1/8/2018, 8:39 AM
`
`

`

`mifepristone | C29H35NO2 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/55245#section=Top
`
`Prescription Drug Products: 1 of 2 (RX Drug Ingredient)
`Drug Ingredient
`MIFEPRISTONE
`Proprietary Name
`MIFEPREX
`Applicant
`DANCO LABS LLC (Application Number: N020687)
`
`from FDA Orange Book
`
`Prescription Drug Products: 2 of 2 (RX Drug Ingredient)
`Drug Ingredient
`MIFEPRISTONE
`Proprietary Name
`KORLYM
`Applicant
`CORCEPT THERAP (Application Number: N202107. Patents: 8921348, 9829495)
`
`from FDA Orange Book
`
`7.6 Drug Labels for Ingredients
`
`Label Title
`Drug Ingredient
`
`KORLYM- mifepristone tablet
`MIFEPRISTONE
`
`Label Image
`
`Label Download
`
`PDF Label
`
`NDC Code(s)
`
`Packager
`
`NDC Code(s)
`76346-073-01, 76346-073-02
`Corcept Therapeutics Inc
`
`7.7 Drugs at PubMed Health
`
`Drugs at PubMed Health: 1 of 2 (PubMed Health Drug Name)
`Drug Name
`Korlym
`
`from DailyMed
`
`24 of 56
`
`1/8/2018, 8:39 AM
`
`

`

`mifepristone | C29H35NO2 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/55245#section=Top
`
`Drugs at PubMed Health: 1 of 2 (PubMed Health Drug Name)
`Notes
`See Mifepristone (By mouth)
`
`from PubMed Health
`
`Drugs at PubMed Health: 2 of 2 (PubMed Health Drug Name)
`Drug Name
`Mifepristone (By mouth)
`Ends a pregnancy that is less than 10 weeks along (70 days or less since the start
`of your last menstrual period). Also used to control high blood sugar in patients
`with Cushing syndrome.
`Antiglucocorticoid, Antiprogesterone
`
`Drug Classes
`
`Description
`
`7.8 Clinical Trials
`
`1 to 5 of 102
`Record ID
`
`View More
`Title
`
`NCT03346629 Outpatient Service for Mid-trimester Termination of Pregnancy
`
`NCT03320057 Medication Abortion Via Pharmacy Dispensing
`
`NCT03269279 Mifepristone and Misoprostol for 2nd Trimester Termination of Pregnancy
`in Burkina Faso
`NCT03259542 Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor
`NCT03258372 Crossover Drug-Drug Interaction Study to Determine Effects of
`Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites
`
`from PubMed Health
`
`Download
`
`Status
`Not yet
`recruiting
`Not yet
`recruiting
`
`Recruiting
`
`Recruiting
`
`Completed
`
`Phase
`
`4
`
`4
`
`3
`
`1
`
`1
`
`from ClinicalTrials.gov
`
`7.9 Therapeutic Uses
`Abortifacient Agents, Steroidal; Contraceptives, Oral, Synthetic; Contraceptives, Postcoital, Synthetic; Hormone
`Antagonists; Luteolytic Agents; Menstruation-Inducing Agents
`National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
`
`from HSDB
`
`Mifepristone is indicated in combination with misoprostol for the medical termination of intrauterine pregnancy of 49
`days duration or less. /Included in US product labeling/
`Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the
`United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1971
`
`25 of 56
`
`1/8/2018, 8:39 AM
`
`

`

`mifepristone | C29H35NO2 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/55245#section=Top
`
`from HSDB
`
`7.10 Drug Warning
`Confirmed or suspected ectopic pregnancy, undiagnosed adnexal mass, or IUD currently in place. Chronic adrenal
`failure or concurrent long-term corticosteroid therapy. Known hypersensitivity to mifepristone, misoprostol, or other
`prostaglandins. Hemorrhagic disorders, inherited porphyrias, or concurrent anticoagulant therapy.
`McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System
`Pharmacists, Inc. 2005 (Plus Supplements)., p. 3148
`
`from HSDB
`
`Vaginal bleeding that is heavier than associated with a normal menses occurs in almost all women receiving
`mifepristone and misoprostol. Based on clinical studies, bleeding or spotting should be expected for an average of
`9-16 days. ... Excessive bleeding may require treatment with vasoconstrictors, saline infusions, and/or blood
`transfusions or curettage.
`McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System
`Pharmacists, Inc. 2005 (Plus Supplements)., p. 3148
`
`from HSDB
`
`Severe vaginal bleeding may occur following spontaneous, surgical, or medical abortion (including following
`mifepristone administration). Prolonged heavy vaginal bleeding (i.e. soaking through 2 thick full-size sanitary pads per
`hour for 2 consecutive hours) may be a sign of incomplete abortion or other complications, and prompt medical or
`surgical intervention maybe required to prevent the development of hypovolemic shock. Patients should be advised to
`seek immediate medical attention if prolonged heavy vaginal bleeding or syncope occurs following mifepristone
`administration.
`McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System
`Pharmacists, Inc. 2005 (Plus Supplements)., p. 3148
`
`from HSDB
`
`Serious bacterial infections (including very rare cases of fatal septic shock) have been reported following mifepristone
`administration; a causal relationship to the mifepristone-misoprostol regimen has not been established. Clinicians
`should consider the possibility of infection if sustained fever (temperature of 38 degrees C or higher persisting for
`more than 4 hours), severe abdominal pain, or pelvic tenderness occurs within several days of medical abortion.
`Atypical presentations of serious infection and sepsis (i.e., presence of significant leukocytosis, tachycardia, or
`hemoconcentration without fever, severe abdominal pain, pelvic tenderness) may also occur.
`McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System
`Pharmacists, Inc. 2005 (Plus Supplements)., p. 3148
`
`from HSDB
`
`A clinical examination or ultrasonagraphic scan should be performed approximately 14 days after mifepristone
`administration to confirm termination of pregnancy. Lack of bleeding usually indicates failure to terminate the
`pregnancy; however, prolonged or heavy bleeding is not proof of a complete abortion. Failure of medical abortion
`after mifepristone and misoprostol should be managed with surgical termination; approximately 5-8% of patients may
`require a surgical procedure to terminate the pregnancy or to avert excessive bleeding. Fetal harm may occur if
`pregnancy continues to term after administration of mifepristone and misoprostol.
`McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System
`Pharmacists, Inc. 2005 (Plus Supplements)., p. 3148
`
`26 of 56
`
`from HSDB
`
`1/8/2018, 8:39 AM
`
`

`

`mifepristone | C29H35NO2 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/55245#section=Top
`
`Mifepristone is not effective for the termination of ectopic pregnancy and is contraindicated for use in patients with
`confirmed or suspected ectopic pregnancy.
`McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System
`Pharmacists, Inc. 2005 (Plus Supplements)., p. 3148
`
`from HSDB
`
`Myocardial infarction occurred in at least one patient 3 days following use of mifepristone and vaginal misoprostol; a
`causal relationship to the regimen has not been established.
`McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System
`Pharmacists, Inc. 2005 (Plus Supplements)., p. 3148
`
`from HSDB
`
`Mifepristone should be prescribed by clinicians who are able to assess the gestational age of an embryo and to
`diagnose ectopic pregnancy. Clinicians also must be able to provide surgical intervention in cases of incomplete
`abortion or severe bleeding or ensure that such services are available from others, and patients must have access to
`medical facilitirs equipped to provide blood transfusions and resuscitation if necessary.
`McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System
`Pharmacists, Inc. 2005 (Plus Supplements)., p. 3148
`
`from HSDB
`
`As with a surgical abortion, preventive measures to suppress formation of anti-RhO (D) antibodies (e.g., administration
`of RhO (D) immune globulin) should be considered in RhO (D)-negative women.
`McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System
`Pharmacists, Inc. 2005 (Plus Supplements)., p. 3148
`
`from HSDB
`
`Safety, efficacy, and pharmacokinetics of mifepristone have not been studied in patients with chronic medical
`conditions (e.g., severe anemia, insulin-dependent diabetes mellitus, hypertension, cardiovascular, respiratory hepatic,
`or renal disease) or a history of heavy smoking. Use caution with women older than 35 years of age who smoke 100 or
`more cigarettes daily, since such patients generally were excluded from clinical studies.
`McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System
`Pharmacists, Inc. 2005 (Plus Supplements)., p. 3148
`
`from HSDB
`
`Not known whether mifepristone is distributed into milk; many hormones with similar structure are distributed into
`breast milk. Consider discarding milk for several days if used in nursing women.
`McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System
`Pharmacists, Inc. 2005 (Plus Supplements)., p. 3148
`
`from HSDB
`
`Safety and efficacy not established in females younger than 18 years of age.
`McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System
`Pharmacists, Inc. 2005 (Plus Supplements)., p. 3148
`
`from HSDB
`
`Adverse effects occurring in 1% or more of patients receiving mifepristone include abdominal pain, nausea, headache,
`vomiting, diarrhea, dizziness, fatigue, back pain, uterine hemorrhage, fever, viral infections, vaginitis, rigors, dyspepsia,
`insomnia, asthenia, leg pain, anxiety, anemia, leukorrhea, sinusitis, syncope, endometritis, salpingitis, pelvic
`inflammatory disease, hemoglobin decreases exceeding 2 g/dL, pelvic pain, and fainting.
`
`27 of 56
`
`1/8/2018, 8:39 AM
`
`

`

`mifepristone | C29H35NO2 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/55245#section=Top
`
`McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System
`Pharmacists, Inc. 2005 (Plus Supplements)., p. 3148
`
`from HSDB
`
`Adverse events indicating need for medical attention only if they continue or are Bothersome: Incidence more
`frequent abdominal pain or uterine cramping; back pain; diarrhea; dizziness; fatigue; headache, or nausea and
`vomiting. Incidence less frequent anemia; anxiety; asthenia; dyspepsia; fever; insomnia; leg pain ; leukorrhea; rigors (
`shaking chills ); sinusitis; syncope; vaginitis or viral Infection.
`Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the
`United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1972
`
`from HSDB
`
`28 of 56
`
`1/8/2018, 8:39 AM
`
`

`

`mifepristone | C29H35NO2 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/55245#section=Top
`
`8.1 Pharmacology
`Mifepristone is a synthetic steroid with antiprogestational effects indicated for the medical termination of intrauterine
`pregnancy through 49 days' pregnancy. Doses of 1 mg/kg or greater of mifepristone have been shown to antagonize
`the endometrial and myometrial effects of progesterone in women. During pregnancy, the compound sensitizes the
`myometrium to the contraction-inducing activity of prostaglandins. Mifepristone also exhibits antiglucocorticoid and
`weak antiandrogenic activity. The activity of the glucocorticoid dexamethasone in rats was inhibited following doses of
`10 to 25 mg/kg of mifepristone. Doses of 4.5 mg/kg or greater in human beings resulted in a compensatory elevation
`of adrenocorticotropic hormone (ACTH) and cortisol.
`
`from DrugBank
`
`Mifepristone is a derivative of the synthetic progestin norethindrone with antiprogesterone activity. Mifepristone
`competitively binds to the progesterone receptor, resulting in inhibition of the effects of endogenous or exogenous
`progesterone. This agent also exhibits antiglucocorticoid and weak antiandrogenic activities.
`
`8.2 MeSH Pharmacological Classification
`
`Contraceptives, Oral, Synthetic
`Oral contraceptives which owe their effectiveness to synthetic preparations.
`See a list of PubChem compounds matching this category.
`
`from NCIt
`
`from MeSH
`
`Hormone Antagonists
`Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones,
`or the action of hormones upon their specific sites.
`See a list of PubChem compounds matching this category.
`
`Contraceptives, Postcoital, Synthetic
`Postcoital contraceptives which owe their effectiveness to synthetic preparations.
`See a list of PubChem compounds matching this category.
`
`Luteolytic Agents
`Chemical compounds causing LUTEOLYSIS or degeneration.
`See a list of PubChem compounds matching this category.
`
`Abortifacient Agents, Steroidal
`Steroidal compounds with abortifacient activity.
`See a list of PubChem compounds matching this category.
`
`from MeSH
`
`from MeSH
`
`from MeSH
`
`29 of 56
`
`1/8/2018, 8:39 AM
`
`

`

`mifepristone | C29H35NO2 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/55245#section=Top
`
`Menstruation-Inducing Agents
`Chemical compounds that induce menstruation either through direct action on the reproductive organs or through
`indirect action by relieving another condition of which amenorrhea is a secondary result. (From Dorland, 27th ed)
`See a list of PubChem compounds matching this category.
`
`from MeSH
`
`from MeSH
`
`8.3 FDA Pharmacological Classification
`
`8.3.1 Active Moiety
`MIFEPRISTONE
`
`8.3.2 FDA UNII
`320T6RNW1F
`
`8.3.3 Pharmacological Classes
`
`Mechanisms of Action [MoA]
`Established Pharmacologic
`Class [EPC]
`
`Progestational Hormone Receptor Antagonists
`
`Progestin Antagonist
`
`from FDA Pharm Classes
`
`from FDA Pharm Classes
`
`from FDA Pharm Classes
`
`8.4 ATC Code
`G03XB01 - Mifepristone < G03XB - Progesterone receptor modulators < G03X - Other sex hormones and modulators
`of the genital system < G03 - Sex hormones and modulators of the genital system < G - Genito urinary system and sex
`hormones
`More information...
`
`8.5 Absorption, Distribution and Excretion
`The absolute bioavailability of a 20 mg oral dose is 69%
`
`from WHO ATC
`
`from DrugBank
`
`30 of 56
`
`1/8/2018, 8:39 AM
`
`

`

`mifepristone | C29H35NO2 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/55245#section=Top
`
`Route of Elimination
`Fecal: 83%; Renal: 9%.
`
`from DrugBank
`
`The absolute bioavailability of oral mifepristone is 69%.
`Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the
`United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1971
`
`from HSDB
`
`Protein binding: Very high (98%); predominantly to albumin and alpha1- acid glycoprotein.
`Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the
`United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1971
`
`from HSDB
`
`Time to peak concentration: 90 minutes after a 600 mg oral dose.
`Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1.